Transaction details
Aeluma, Inc. reported a sale of company stock by Chief Executive Officer Jonathan Klamkin in a Form 4 filed with the Securities and Exchange Commission. The filing records that on April 1, 2026, Klamkin sold 20,000 shares of the company's common stock at a weighted average price of $13.0975, producing proceeds of $261,950. The reported execution prices for the sale ranged from $12.82 to $13.325.
Holdings and trading plan
Following the disposition, Klamkin retains direct ownership of 1,409,398 shares of Aeluma. The transaction was carried out pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2025.
Share performance context
At the time of the report, Aeluma's common stock was trading at $13.44. The stock has ranged from a 52-week low of $5.79 to a 52-week high of $25.88, and the company has posted a 105% return over the last year.
Recent operating results and guidance
Aeluma disclosed a decline in revenue for its second fiscal quarter of 2026, reporting revenue of $1.3 million compared with $1.6 million in the same quarter a year earlier. The company recorded a GAAP net loss of $1.9 million, or $0.11 per share, for the quarter. Despite the quarterly declines, Aeluma issued full-year revenue guidance of between $4 million and $6 million.
Capital markets activity and analyst coverage
In a separate corporate development, Aeluma established an at-the-market equity sales agreement enabling the offering and sale of up to $50 million of common stock through Roth Capital Partners and other placement agents. On the analyst front, Freedom Capital Markets initiated coverage of Aeluma with a buy rating and a $23.00 price target, citing the company's proprietary heteroepitaxy process. Benchmark reiterated a Buy rating with a $25.00 price target, referencing Nvidia's strategic investments in optical connectivity as context for its view.
Management appointment
The company also announced the appointment of Christiane Poblenz as Vice President of Materials Operations. The hire is intended to support the scaling of Aeluma's epitaxial wafer production.
Valuation note
According to InvestingPro analysis, Aeluma currently appears overvalued relative to its Fair Value. Pro research and related analyst materials are available for investors seeking additional context on the company's financial position and prospects.
What this filing shows
The Form 4 disclosure confirms an insider sale executed under a pre-established trading plan and provides updated information about the CEO's shareholdings. The filing sits alongside a series of corporate updates that include the quarterly results, guidance, an equity program, analyst coverage, and a senior operations hire.